Current clinical guidelines suggest methylphenidate (MPH) as first-line option for treatment of attention-deficit/hyperactivity disorder (ADHD). However, the Lombardy ADHD Registry initiative has recently raised some concerns about discrepant therapeutic approaches between different clinical centers. In this naturalistic observational study, we report the experience of a third-level referral center in monitoring care services for young ADHD patients. We described the clinical characteristics of…
